Healthcare Industry News: TomoTherapy
News Release - August 24, 2010
TomoTherapy Enables General Hospital of Guangzhou Military Command of PLA to Provide Advanced Care to Patients With Head and Neck CancersInstallation of TomoTherapy(R) Treatment System Is First in Southern China
MADISON, WI--(Healthcare Sales & Marketing Network) - TomoTherapy Incorporated (NASDAQ:TOMO ), maker of advanced, integrated radiation therapy solutions for cancer care, announced today that General Hospital of Guangzhou Military Command of PLA has purchased the first TomoTherapy® radiation therapy system to be installed in Southern China. The TomoTherapy treatment system will enable the hospital to provide advanced cancer care to a wide variety of patients, including those with head and neck cancers.
"In this area of Southern China, we see a large number of patients who suffer from head and neck cancers. But our aging linear accelerator technology has limited our ability to treat these patients, forcing us to refer them to other cancer centers," said Jian Liu, president of PLA Guangzhou Hospital, which treats more than 1 million patients annually. "The TomoTherapy platform will enable us to expand our care and deliver treatments for the most complicated cases very effectively and accurately with its integrated daily 3-D imaging."
The TomoTherapy radiation therapy system allows clinicians to provide helical image-guided, intensity-modulated radiation therapy (IG-IMRT), which has been shown to offer better dosimetric distributions when compared to traditional IMRT treatments. PLA Guangzhou will use the TomoTherapy treatment system to address complex nasopharyngeal cancer cases, in which patients can suffer significant side effects. The daily megavoltage CT (MVCT) imaging offered by the TomoTherapy treatment system will allow clinicians at PLA Guangzhou General Hospital to better monitor changes to the parotid glands, and calculate the dosage they receive. In addition, the TomoTherapy system's innovative adaptive planning capabilities enable clinicians to quickly and easily re-plan treatment so that the dosage received is optimized over the course of treatment.
"With its plan to focus its TomoTherapy treatments on complex head and neck cancers, we believe that PLA Guangzhou General Hospital will quickly become one of the premier locations for these types of treatments in Southern China," said Fred Robertson, CEO of TomoTherapy. "We are happy to continue our strong relationship with our distributor TomoKnife to expand access to TomoTherapy technology for the benefit of clinicians and patients throughout China."
About TomoTherapy Incorporated
TomoTherapy Incorporated develops, markets and sells advanced radiation therapy solutions that can be used to treat a wide variety of cancers, from the most common to the most complex. The ring gantry-based TomoTherapy® platform combines integrated CT imaging with conformal radiation therapy to deliver sophisticated radiation treatments with speed and precision while reducing radiation exposure to surrounding healthy tissue. TomoTherapy's suite of solutions include its flagship Hi-Art® treatment system, which has been used to deliver more than three million CT-guided, helical intensity-modulated radiation therapy (IMRT) treatment fractions; the TomoHD™ treatment system, designed to enable cancer centers to treat a broader patient population with a single device; and the TomoMobile™ relocatable radiation therapy solution, designed to improve access and availability of state-of-the-art cancer care. TomoTherapy's stock is traded on the NASDAQ Global Select Market under the symbol TOMO. To learn more about TomoTherapy, please visit TomoTherapy.com.
Statements in this release regarding future products or product capabilities, events, expectations and other similar matters, including but not limited to statements using the terms "may," "should," "suggests" or "indicates" constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements contained in this press release are subject to risks and uncertainties that could cause actual results to differ materially from those anticipated, including but not limited to factors such as our ability to integrate acquired assets, ability to protect intellectual property, risks of interruption due to events beyond the company's control, and the other risks listed from time to time in TomoTherapy's filings with the U.S. Securities and Exchange Commission, which by this reference are incorporated herein. These forward-looking statements represent TomoTherapy's judgments as of the date of this press release. TomoTherapy assumes no obligation to update or revise the forward-looking statements in this release because of new information, future events or otherwise.
©2010 TomoTherapy Incorporated. All rights reserved. TomoTherapy, Tomo, TomoDirect, TQA, the TomoTherapy logo and Hi-Art are among trademarks, service marks or registered trademarks of TomoTherapy Incorporated in the United States and other countries.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.